Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) shares hit a new 52-week low during mid-day trading on Monday. The stock traded as low as $11.12 and last traded at $11.18, with a volume of 56,449 shares. The stock had previously closed at $11.37.
Janux Therapeutics News Summary
Investors following JANX have been watching these news items:
- Positive Sentiment: HC Wainwright raised its projected earnings per share (EPS) for Q4 2026 and each quarter of 2027, reflecting smaller expected losses. It also improved its full-year estimates for 2026 (to a loss of $1.48 per share from $1.69) and 2027 (to a loss of $1.92 from $2.36). Janux analyst estimate updates
- Neutral Sentiment: HC Wainwright reiterated its Buy rating, though its revised estimates still project losses in the coming years. Janux analyst estimate updates
- Negative Sentiment: The analyst cut its longer-term EPS forecasts: 2028 edged lower, while 2029 and 2030 were revised substantially down to losses of $3.06 and $2.04 per share, respectively. Those weaker outlooks could offset the improved near-term projections. Janux analyst estimate updates
Analyst Ratings Changes
A number of research analysts recently weighed in on the stock. Wedbush raised their target price on shares of Janux Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 6th. HC Wainwright reaffirmed a “buy” rating on shares of Janux Therapeutics in a research note on Thursday. Wolfe Research downgraded shares of Janux Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Thursday. TD Cowen upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Guggenheim dropped their price objective on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Janux Therapeutics has an average rating of “Moderate Buy” and an average target price of $36.92.
Read Our Latest Research Report on Janux Therapeutics
Janux Therapeutics Stock Performance
The company has a market cap of $658.94 million, a PE ratio of -6.77 and a beta of 2.44. The company has a fifty day moving average of $16.80 and a two-hundred day moving average of $15.35.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.13. The firm had revenue of $9.29 million for the quarter, compared to analysts’ expectations of $8.03 million. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.59 EPS for the current year.
Institutional Investors Weigh In On Janux Therapeutics
Several institutional investors have recently made changes to their positions in the company. Diversified Trust Co grew its position in shares of Janux Therapeutics by 3.5% during the 3rd quarter. Diversified Trust Co now owns 17,429 shares of the company’s stock worth $301,000 after buying an additional 588 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Janux Therapeutics by 67.4% during the third quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after buying an additional 661 shares during the period. Versant Capital Management Inc raised its holdings in shares of Janux Therapeutics by 42.8% in the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after acquiring an additional 784 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in shares of Janux Therapeutics by 8.8% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 12,350 shares of the company’s stock valued at $213,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Bleakley Financial Group LLC lifted its stake in Janux Therapeutics by 6.8% in the third quarter. Bleakley Financial Group LLC now owns 21,262 shares of the company’s stock worth $367,000 after acquiring an additional 1,363 shares during the period. Institutional investors own 75.39% of the company’s stock.
Janux Therapeutics Company Profile
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors. Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.
Featured Articles
- Five stocks we like better than Janux Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
